This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pruneri, G. Articles by Neri, A. Search for Related Content PubMed PubMed Citation Articles by Pruneri, G. Articles by Neri, A.

(American Journal of Pathology. 2000;156:1505-1513.)
© 2000 American Society for Investigative Pathology

Short Communications

Immunohistochemical Analysis of Cyclin D1 Shows Deregulated Expression in Multiple Myeloma with the t(11;14)

Giancarlo Pruneri^*, Sonia Fabris^*, Luca Baldini^*, Nadia Carboni, Savina Zagano^*, Maria Angela Colombi^*, Gabriella Ciceri^*, Luigia Lombardi^*, Mariano Rocchi, Roberto Buffa, Anna Teresa Maiolo^* and Antonino Neri^*

From the Laboratorio di Ematologia Sperimentale e Genetica Molecolare,^*
Servizio di Ematologia, Milano; the Servizio di Anatomia Patologica,
Università degli Studi di Milano, Ospedale Maggiore IRCCS, Milano; and the Istituto di Genetica,
Università di Bari, Bari, Italy

The t(11;14)(q13;q32) chromosomal translocation, the hallmark of mantle cell lymphoma (MCL), is recurrently found in multiple myelomas (MM) by means of conventional cytogenetics. Unlike MCL, recent molecular studies of MM-derived cell lines with t(11;14) have indicated that the breakpoints are highly dispersed over the 11q13 region; however, the fact that cyclin D1 is generally overexpressed in these cell lines suggests that this gene is the target of the translocation. To evaluate further the involvement of cyclin D1 in MM, we used immunohistochemistry and fluorescence in situ hybridization to investigate cyclin D1 expression and the presence of chromosome 11 abnormalities in a representative panel of 48 MM patients (40 at diagnosis and 8 at relapse). Cyclin D1 overexpression occurred in 12/48 (25%) of cases; combined immunohistochemistry and fluorescence in situ hybridization analyses in 39 patients showed cyclin D1 positivity in all of the cases (7/7) bearing the t(11;14), in two of the 13 cases with trisomy 11, and in one of the 19 cases with no apparent abnormalities of chromosome 11. Our data indicate that the t(11;14) translocation in MM leads to cyclin D1 overexpression and that immunohistochemical analysis may represent a reliable means of identifying this lesion in MM.

This article has been cited by other articles:

				J Yeung and H Chang Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma J. Clin. Pathol., July 1, 2008; 61(7): 832 - 836. [Abstract] [Full Text] [PDF]

				L. Agnelli, S. Bicciato, M. Mattioli, S. Fabris, D. Intini, D. Verdelli, L. Baldini, F. Morabito, V. Callea, L. Lombardi, et al. Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations J. Clin. Oncol., October 10, 2005; 23(29): 7296 - 7306. [Abstract] [Full Text] [PDF]

				K. Specht, E. Haralambieva, K. Bink, M. Kremer, S. Mandl-Weber, I. Koch, R. Tomer, H. Hofler, E. Schuuring, P. M. Kluin, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels Blood, August 15, 2004; 104(4): 1120 - 1126. [Abstract] [Full Text] [PDF]

				S. Soverini, M. Cavo, C. Cellini, C. Terragna, E. Zamagni, D. Ruggeri, N. Testoni, P. Tosi, A. de Vivo, M. Amabile, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation Blood, September 1, 2003; 102(5): 1588 - 1594. [Abstract] [Full Text] [PDF]

				L. Quintanilla-Martinez, M. Kremer, K. Specht, J. Calzada-Wack, M. Nathrath, R. Schaich, H. Hofler, and F. Fend Analysis of Signal Transducer and Activator of Transcription 3 (Stat 3) Pathway in Multiple Myeloma: Stat 3 Activation and Cyclin D1 Dysregulation Are Mutually Exclusive Events Am. J. Pathol., May 1, 2003; 162(5): 1449 - 1461. [Abstract] [Full Text] [PDF]

				M. Sanchez-Beato, A. Sanchez-Aguilera, and M. A. Piris Cell cycle deregulation in B-cell lymphomas Blood, February 15, 2003; 101(4): 1220 - 1235. [Abstract] [Full Text] [PDF]

				K. Specht, M. Kremer, U. Muller, S. Dirnhofer, M. Rosemann, H. Hofler, L. Quintanilla-Martinez, and F. Fend Identification of Cyclin D1 mRNA Overexpression in B-Cell Neoplasias by Real-Time Reverse Transcription-PCR of Microdissected Paraffin Sections Clin. Cancer Res., September 1, 2002; 8(9): 2902 - 2911. [Abstract] [Full Text] [PDF]

				R. Fonseca, E. A. Blood, M. M. Oken, R. A. Kyle, G. W. Dewald, R. J. Bailey, S. A. Van Wier, K. J. Henderson, J. D. Hoyer, D. Harrington, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients Blood, May 15, 2002; 99(10): 3735 - 3741. [Abstract] [Full Text] [PDF]

				B. Falini and D. Y. Mason Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry Blood, January 15, 2002; 99(2): 409 - 426. [Abstract] [Full Text] [PDF]

				J. Shaughnessy Jr, A. Gabrea, Y. Qi, L. Brents, F. Zhan, E. Tian, J. Sawyer, B. Barlogie, P. L. Bergsagel, and M. Kuehl Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma Blood, July 1, 2001; 98(1): 217 - 223. [Abstract] [Full Text] [PDF]